Acute myeloid leukemia: advancing clinical trials and promising therapeutics

Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?

(2016) Armin Rashidi et al.   Expert Review of Hematology

Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility

(2016) Hsin-An Hou et al.   Expert Review of Hematology

Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy

(2016) Caroline Bret et al.   Expert Review of Hematology

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

(2015) Courtney D. DiNardo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Getting a handle on hereditary CEBPA mutations

(2015) C. D. DiNardo   BLOOD

Secondary mutations as mediators of resistance to targeted therapy in leukemia

(2015) N. Daver et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification

(2015) P. Strati et al.   BLOOD

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

(2015) Tapan M. Kadia et al.   CANCER

Combined immunodeficiency with CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation affecting IL21R

(2015) B. Erman et al.   HAEMATOLOGICA

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

(2015) Farhad Ravandi et al.   LANCET ONCOLOGY

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

(2015) Jean-Pierre J Issa et al.   LANCET ONCOLOGY

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication

(2015) Håkon Reikvam et al.   Expert Review of Hematology

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

(2015) Melanie Janning et al.   Expert Review of Hematology

Precision medicine for acute myeloid leukemia

(2015) Catherine Lai et al.   Expert Review of Hematology

Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets

(2015) Håkon Reikvam et al.   Expert Review of Hematology

Combined immunodeficiency with CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation affecting IL21R

(2015) B. Erman et al.   HAEMATOLOGICA

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

(2014) J. E. Lancet et al.   BLOOD

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

(2014) Jorge E. Cortes et al.   CANCER

Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol

(2014) N. Bolli et al.   HAEMATOLOGICA

B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies

(2014) J. P. Vaque et al.   HAEMATOLOGICA

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies

(2014) A P Im et al.   LEUKEMIA

5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

(2014) May Kung Sutherland et al.   mAbs

Crenolanib is a selective type I pan-FLT3 inhibitor

(2014) C. C. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia

(2014) Øystein Bruserud et al.   Expert Review of Hematology

Emergence of crenolanib for FLT3-mutant AML

(2013) A. T. Fathi   BLOOD

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

Targeting IDH: the next big thing in AML

(2013) M. Levis   BLOOD

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

(2013) A. Galanis et al.   BLOOD

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

(2013) A. Chaturvedi et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2013) Xavier G. Thomas et al.   Clinical Lymphoma Myeloma & Leukemia

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute myeloid leukemia in the elderly: do we know who should be treated and how?

(2013) Aziz Nazha et al.   LEUKEMIA & LYMPHOMA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

(2013) J.-A. Losman et al.   SCIENCE

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

(2012) Twee Tsao et al.   ANNALS OF HEMATOLOGY

386 Evaluation of Crenolanib (CP-868,596) for the Treatment of FLT3-ITD-positive AML

(2012) E.I. Zimmerman et al.   EUROPEAN JOURNAL OF CANCER

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

(2012) E.J. Feldman et al.   LEUKEMIA RESEARCH

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

(2011) V. Rockova et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

(2011) Simona Lapusan et al.   INVESTIGATIONAL NEW DRUGS

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

(2011) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

(2011) N Ånensen et al.   ONCOGENE

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

(2010) Michael Crump et al.   LEUKEMIA & LYMPHOMA

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

(2009) S. Metzelder et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects

(2008) B. J. Wouters et al.   BLOOD

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

(2008) Chih-Chen Hong et al.   CANCER LETTERS

Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration

(2008) Giuseppe Straface et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

(2008) C. G. Mullighan et al.   SCIENCE